Clinical Research
Copyright ©The Author(s) 2004.
World J Gastroenterol. May 15, 2004; 10(10): 1521-1525
Published online May 15, 2004. doi: 10.3748/wjg.v10.i10.1521
Figure 1
Open in New Tab Full Size Figure Download Figure
Figure 1 Expressions of NF-κBp65 and IκB in nuclei and cytoplasm. A: Expression of NF-κBp65 in nuclei, B: Expres-sion of IκB in cytoplasm, Lanes1-2: expression before treatment, Lanes3: expression after probiotics treatment, Lanes4: expression in control.
Figure 2
Open in New Tab Full Size Figure Download Figure
Figure 2 Inhibition of NF-κB binding DNA by BIFICO. 1, Cool probe; 2, Activation NF-κB before treatment; 3: Probiotic significantly inhibited activation of NF-κB.
Figure 3
Open in New Tab Full Size Figure Download Figure
Figure 3 Activation of NF-κB in. Placebo group 1, Cool probe; 2, Activation of NF-κB before treatment; 3, Placebo did not obviously inhibit the activation of NF-κB.
Figure 4
Open in New Tab Full Size Figure Download Figure
Figure 4 Expressions of IL-1mRNA, TNF-α mRNA and IL-10 mRNA. A: Expression of IL-1 mRNA, Lanes 1,2: IL-1 mRNA expression before treatment; lane 3: BIFICO inhibited IL-1 mRNA expression; lane 4: IL-1 mRNA expression in placebo group. B: Expression of TNF-α mRNA, Lanes 1, 2, 3, 4 G3PDH; lanes 5, 6: TNF-α mRNA expression before treatment; Lane 7: BIFICO inhibited significantly mRNA expression of TNF-α; lane 8: TNF-α mRNA expression in placebo group. C: Expres-sion of IL-10 mRNA, Lanes 1, 2: IL-10 mRNA before treatment; lane 3: BIFICO enhanced IL-10 mRNA expression; lane 4: IL-10 mRNA in placebo group.